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Essential  thrombocythemia  (ET),  a chronic  myeloproliferative  disease,  is  characterized  by an  increased
number  of  platelets  and  risk of vascular  thrombosis.  A case  of a  patient  treated  for  ET  who  had  acute
myocardial  infarction  (MI)  and  reinfarction  within  a  month  is  presented.  A 55-year-old  male  patient  was
hospitalized  because  of subacute  inferolateral  non-ST-segment-elevation  MI, without  risk  factors  for
cardiovascular  diseases.  The  patient  has  been  treated  for  ET for the  past  8 years,  received  anagrelide  for
the past  two years.  The  ﬁrst  coronary-angiography  did  not  detect  signiﬁcant  stenosis  of epicardial  vessels;
the  patient  was  discharged  in stable  condition  with  anagrelide  therapy.  Two  weeks  later,  the  patient  had
an acute  anterolateral  ST-segment-elevation  MI.  Primary  percutaneous  coronary  intervention  showed
thrombus in the  distal  part  of  the left anterior  descending  coronary  artery.  Percutaneous  transluminal
coronary  angioplasty  was  performed  and eptiﬁbatide  was  administered  after the  procedure.  There  was no
residual  stenosis,  prescribed  therapy  included  clopidogrel  and  low-molecular-weight  heparin.  Anagrelide
therapy  was  replaced  with  hydroxyurea  (HU)  and acetylsalicylic  acid  (ASA).  It is  necessary  to treat  ET  in
line  with  the standard  treatment  protocol  for coronary  diseases.  In  the  treatment  of high-risk  hematology
patients  anagrelide  proved  to be a worse  option  than  the  combination  of  HU and  ASA.
<Learning  objective:  It is  known  that the  myeloproliferative  disorders  carry the risk of  vascular  throm-
bosis  and  myocardial  infarction.  The  occurrence  of  vascular  events  is  usually  the  ﬁrst  sign  of  the  disease.
A  case  of a patient  with  history  of  hematological  disease,  who  was  receiving  active  treatment  and  was
well-regulated  with  oral  medication,  is presented  here.  Various  approaches  to treatment  of  such  patients
are  possible  and  treatment  decision-making  is important  for  clinicians.  Therefore,  this  article  presents
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Essential thrombocythemia (ET) is a chronic myeloprolifera-
ive disease characterized by thrombocytosis with a bone marrow
egakaryocyte hyperplasia and increased risk of vascular events,
rterial and/or venous [1]. This heterogeneous group of diseases
lso includes polycythemia vera, idiopathic myeloﬁbrosis, and
hronic myelogeneous leukemia [2]. Transition from one disor-
er to another is possible. Acquired mutation in JAK2 gene is
iscovered in a high proportion in patients with Philadelphia chro-
osome negative myeloproliferative disease, which provides a
olecular basis for integration of these entities [3–6]. ET affects the
atient’s quality of life more than their survival and thus has more
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878-5409/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
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favorable prognosis than other myeloproliferative disorders [7].
The challenge in treating ET is prevention of bleeding and throm-
bosis without increasing the risk of complications, such as paradox
thrombosis, hemorrhage, or the progression of the disease into
myeloﬁbrosis or acute leukemia.
A case of a 55-year-old male patient suffering from ET for the
past eight years is presented in this article. He received anagrelide
therapy for the past two years. Despite active treatment, he has
had acute myocardial infarction and reinfarction within one month.
The aim of this article is to put greater emphasis on the problem of
treating such patients.
Case reportA 55-year-old male patient was  hospitalized in the coronary
care unit because of subacute non-ST segment elevation myocardial
infarction (NSTEMI). There was  no family history of cardiovascular
vier Ltd. All rights reserved.
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Fig. 1. (a) Normal angiogram of left anterior descending artery (LAD) and left cir-
cumﬂex artery after ﬁrst myocardial infarction and (b) distal occlusion of LAD duringI. Bosˇnjak et al. / Journal of C
iseases and no major risk factors (hypertension, diabetes mellitus,
yslipidemia, smoking) for development of cardiovascular diseases
n the patient’s medical history. The patient has suffered from ET for
he past eight years. During the ﬁrst six years he was  treated with
ydroxyurea (HU) and acetylsalicylic acid (ASA). This therapy was
iscontinued and replaced with anagrelide, while the patient com-
lained of itching of the palms, which was suspected to be related
o the previous therapy. Electrocardiogram showed ischemia of
he inferolateral wall of the myocardium. Table 1 presents labo-
atory characteristics of the patient. Calculated Grace Score was
0.6 with 3% probability of dying from admission to six months
fter the discharge from hospital. In consultation with the hema-
ologist, the patient was treated with anagrelide but without ASA,
ow weight molecular heparin (LWMH), angiotensin-converting
nzyme inhibitor (ACEI), statin, omega-3-acid, and long-acting
itrates. The coronary angiography did not detect any signiﬁ-
ant stenosis of major epicardial vessels (Fig. 1a). The patient was
ischarged from hospital in a stable condition with blood concen-
ration of platelets of 706 × 109/L. Two weeks after the discharge,
he patient was hospitalized again because of acute anterolateral
T-segment elevation myocardial infarction (STEMI). A primary
ercutaneous coronary intervention (PPCI) was done and thrombus
as found in the distal part of the left descending coronary artery
LAD) (Fig. 1b). Percutaneous transluminal coronary angioplasty
PTCA) was then performed to open the blocked coronary artery
nd to restore arterial blood ﬂow to the heart tissue. There was  no
esidual stenosis of the target coronary artery and no indication for
tent implantation. Infusion of eptiﬁbatide was also administered.
o major complication occurred after the intervention. Echocar-
iographic ﬁndings after both coronary incidents indicated proper
eft ventricular ejection fraction with diastolic dysfunction of the
rst degree. The therapy included clopidogrel, ACEI, statin, omega-
-acyd, LWMH,  and trimetazidim. Anagrelide was  replaced with
U and ASA. Beta blocker was not given, as the patient had a low
eart rate frequency.
iscussion
ET is the most common among chronic myeloproliferative
onoclonal neoplasms [8]. The disease appears at all ages and
s prevalent in women [9]. Most patients are asymptomatic at
resentation. Vascular events are the most common clinical man-
festation of the disease and arterial thromboses are more often
han venous [10–12]. Acute coronary syndrome occurs in 9.4% of
atients with essential thrombocytosis [13]. Smoking and hyper-
ension are the risk factors for ischemic arterial complications
able 1
aboratory characteristic.
RBC 3.76 × 1012/L (4.34–5.72 × 1012/L), Hb 114 g/L (138–175 g/L), Hct 0.337
(0.415–0.530)
WBC  15.5 × 109/L (3.4–9.7 × 109/L)
Plts 840 × 109/L (158–424 × 109/L)
PT 1.18 1 (0.70–1.27 1), APTT 0.97 (0.8–1.2), TT 15.8 s (14–21 s), BT 0.07 s
(0.06–0.24 s), protein C 1.40 (0.69–1.56), vWF  0.72 1 (0.50–1.50 1),
thrombocyte aggregation to ristocetin 2 U (90–201 U), LAC 1.27 aCL screen,
anti-2GPI negative, JAK2 mutation negative
TnI 88.000 g/L (0.000–0.056 g/L), CK 1247 U/L (0–177 U/L), CK-MB 123 U/L
(0–24 U/L)
Na 134 mmol/L (137–146 mmol/L), K 4.3 mmol/L (3.9–5.1 mmol/L), urea
5.4 mmol/L (2.8–8.3 mmol/L), creatinine 78 mol/L (42–80 mol/L)
LDH 224 U/L (130–241 U/L), cholesterol 3.03 mmol/L (<5 mmol/L), LDL-C
1.19 mmol/L (<3 mmol/L), HDL-C 0.92 mmol/L (>1 mmol/L), triglyceride
2.03 mmol/L (<1.7 mmol/L)
BC, red blood cell; Hb, hemoglobin; Hct, hematocrit; WBC, white blood cell; Plts,
latelets; PT, prothrombin time; APTT, activated partial thromboplastin time; TT,
hrombotic time; BT, bleeding time; vWF, von Wilebrand factor; LAC, lupus antico-
gulant; aCL, anticardiolipin; anti-2GPI, anti-beta2 glycoprotein I.second myocardial infarction.
in patients with essential thrombocytosis [14]. The pathogenesis
of thrombosis in ET has not been clariﬁed. Along with smoking
and hypertension, advanced age and previous history of throm-
bosis are the most important factors for vascular manifestation
in ET [8,10,15]. There is no correlation between platelet blood
level and the risk of thrombosis [16]. The possible importance of
leukocytes and JAK2 mutation in development of thrombosis in
monoclonal neoplasm has been researched in many studies [7,17].
The results of these studies tend to support a contributory role of
higher leukocyte counts and JAK2 mutation status and allele bur-
den for development of thrombosis [16]. Leukocytes in ET patients
have an activated phenotype with increased phagocytosis, overex-
pression of the membrane CD11b antigen and leukocyte alkaline
phosphatase, and increased plasmatic and cellular elastase content
[18]. Overexpression of monocyte tissue factor, currently consid-
ered the main trigger of the coagulation cascade in vivo, has been
demonstrated in ET patients with thrombosis, and an increased
number of platelets expressing P-selectin has also been found. The
link between leukocyte and platelet activation and thrombosis in
ET has been conﬁrmed by the ﬁnding of increased concentrations of
markers for coagulation and endothelial activation in patients with
increased blood cell activation [18,19]. A vascular event represents
the most frequent complication of ET. That affects the patients’
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uality of life more than their survival rate. Prognostic stratiﬁcation
f ET must be dictated by the patients’ risk of developing such com-
lications and therefore the treatment goal should be to prevent
hrombosis and bleeding without increasing the risk of transfor-
ation of the disease [20]. Recent diagnostic criteria for ET have
owered the platelet threshold from 600 × 109/L to 450 × 109/L [15].
 risk-adapted treatment strategy is an option in the choice of ther-
py. Bearing in mind the possible complications in patients who
uffer from ET (thrombotic events or hemorrhage), there are a few
rugs available for treatment. A young, asymptomatic patient with
 platelet count of less than 1500 × 109/L should be considered at a
ow risk of thrombosis and hemorrhagic events, and does not need
ytoreductive drugs, only ASA [12,21]. By contrast, advanced age of
0 years or more, a history of serious bleeding or thrombosis, or a
latelet level over 1500 × 109/L, are indications for cytoreductive
rugs [21]. The myelosuppressive agent of choice in patients who
uffer from ET and have risk of vascular thrombosis or bleeding is
U [19]. This drug was found to be effective in reducing the inci-
ence of thrombosis [22]. The biggest concern is whether HU carries
he risk of development of leukemia. There is no strong scientiﬁc
vidence for this, but the putative risk of leukemia associated with
U prompted researchers to test some new drugs that lack this
otential, such as anagrelide. Anagrelide is an imidazoquinazoline
erivate that reduces the platelet count in ET [23]. It selectively
nhibits maturation of megakaryocytes, with either minimal or no
ffect on the other blood cell precursors. This might be a solution to
ur problem, and it may  explain why this patient had a myocardial
nfarction twice. Furthermore, according to the results obtained by
arrison and colleagues, HU plus ASA therapy was  superior to ana-
relide plus ASA in patients with ET at high risk of vascular events
24]. Their trial showed that control of platelet count alone should
ot be taken as an appropriate surrogate end point to judge the efﬁ-
iency of treatment for ET. There were more vascular events in the
roup of patients with anagrelide therapy, despite a reduction in the
latelet count that was similar in the HU group. A likely explanation
or this ﬁnding is the myelosuppressive effect of HU which affects
hrombocytes, leukocytes, and erythrocytes [25]. Anagrelide and
SA act synergistically, which increases the risk of bleeding com-
lications due to inhibited platelet function when these two drugs
re administered simultaneously. However, the combination of HU
nd ASA does not have such an effect. A similar result was  obtained
n a patient treated with HU and ASA because of polycythemia vera
26]. Evolution into myeloﬁbrosis is a part of the natural history of
T and it occurs in about 3% of patients after 5 years, in 8% after
0 years, and in 15% after 15 years of the illness [27]. The study by
arrison et al. showed that progression to myleoﬁbrosis was  about
hree times as frequent in the anagrelide group as it was  in the
U group. Transformation into acute leukemia was  similar in both
roups [28].
Treatment of a myocardial infarction as a manifestation of ET
s a great challenge for clinicians. There are some important facts
o be considered in treatment decision-making. Mechanical open-
ng of a blood vessel–by angioplasty, aspiration, or stent placement
oes not present a problem, but there is a question of choos-
ng adequate antiaggregation therapy for treatment of MI,  but
lso of ET. The gold standard in long-term treatment of acute
oronary syndrome is a dual antiplatelet therapy (DAT) with clo-
iodgrel and ASA [29]. ASA is not the optimal choice in patients
ho were treated with anagrelide due to increased risk of hem-
rrhage. By substituting anagrelide with HU, the treatment is
ptimized. PPCI is still the best option in treatment of acute MI
 opening of the occluded blood vessel. When catheterization lab-
ratory is not available, administration of a ﬁbrinolytic therapy is
n alternative. Introduction of unfractionated or LMWH  and glyco-
rotein IIb/IIIa receptor inhibitors are also recommended therapies
29].
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Conclusion
The treatment of patients with ET and myocardial infarction
includes PPCI, elective PCI, emergency coronary artery bypass graft,
or infusion of ﬁbrinolytic agent. The treatment of myocardial infarc-
tion based on myeloproliferative monoclonal diseases requires
special consideration. Standard protocol of treatment for acute
coronary syndrome is effective in most cases, but we must know
that it is crucial to treat the underlying disease as well. According
to new data, the combination of HU and ASA provides the greatest
beneﬁt for the patients with ET and myocardial infarction. There
is much less bleeding and fewer vascular events, and progression
to myeloﬁbrosis and leukemia in the HU/ASA group is lower than
in the anagrelide group. However, there is no simple answer to the
question of how to treat patients with ET and myocardial infarction.
There are insufﬁcient data on the most appropriate way  of treating
these patients, which requires further studies with a larger number
of patients.
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